ClinicalTrials.gg
CompletedNCT02971878Updated Feb 22, 2018

Comparisons of Human Embryonic Development Using Single Medium With and Without the Addition of Antioxidants

An interventional study of Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA) in Culture Media, Blastocyst and Antioxidants, sponsored by Fertilitetscentrum AB. Completed at 1 site in Sweden. Open to participants aged 20 Years to 41 Years. Per ClinicalTrials.gov, last updated 2018-02-22.

Sponsored by Fertilitetscentrum AB · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
20 Years to 41 Years
Sex
All
01

Study summary

Aim: To investigate the impact of antioxidants (acetyl-L-carnitine, N-acetyl-L-cysteine and a-lipoic acid) on embryo development and subsequently the clinical outcome. Including clinics using low oxygen and ambient air during embryo culture. Analysed with time-lapse system.

Study media: G-TL with antioxidants. Control media: Same media without antioxidants. Type of study: Study comparing blastocyst development on the same cohort of oocytes using two different media, G-TL versus G-TL supplemented with antioxidants. Statistics based on an absolute increase in Good Quality Blastocysts on day 5 of 7%.

Design: Multicentre prospective randomized sibling trial. Single blastocyst transfer. Superiority study Primary Endpoint: Good Quality Blastocysts on day 5 per allocated normally fertilized oocyte.

Patients: Comparative embryo sibling study with 128 patients included.

Read the detailed description

Study objective: Study comparing blastocyst development on the same cohort of oocytes using two different media, G-TL versus G-TL supplemented with antioxidants.

Primary endpoint: Percentage of good quality blastocysts (GQB) per fertilized oocyte on day 5.

Secondary endpoints

  • Embryo development day 3, 5 and 6
  • Embryo quality day 3, 5 and 6
  • Total blastocyst formation (day 5 and day 6)
  • Utilization rate (embryos available for transfer and cryopreservation)
  • Implantation rate
  • Clinical pregnancy rate

Setup: Prospective embryo sibling, superiority study

MATERIALS AND METHODS Intervention New type of embryo culture media used for in vitro culture of human IVF embryos.

Power analysis The planning and the power analysis was made together with a statistician, Nils-Gunnar Pehrsson.

From retrospective data using simulation, the intra individual SD for the difference in % GQB between the two media strategies was estimated to 32%. In order to find a difference in 8% in GQB between the two media with power 80% with paired T-test 128 couples will be needed.

Randomization Couples will be enrolled in the study after fertilization check (day 1). A minimum of 6 zygotes is required for participation.

Stratified randomization of the zygotes by couple will be performed. For each couple the zygotes will be numbered.

These zygotes for each couple will then be block (by two) randomized to the two media types; A (Traditional culture media = Control) and B (Antioxidant media = intervention). In both groups traditional culture will be performed. Allocation will be performed in a 1:1 ratio according to a unique randomization list for each couple.

Blinding To minimize possible bias for the primary outcome (GQE D5) the embryologist performing the morphological evaluation on day 5/6 will not know which group the embryos belong to.

Both the physician and the couple will be blinded to which group they have been allocated.

IVF treatment procedure A traditional IVF treatment will be performed including ovarian stimulation and oocyte pick-up using the standard methods at the clinics.

Embryo assessment and timing of assessment according to Alpha/ESHRE consensus criteria.

Morphological scoring Blastocyst morphology will be scored according to Consensus Scoring system for blastocysts (Istanbul Consensus workshop on embryo assessment) and the morphology will be documented with individual photos of each blastocyst. Blastocyst scoring will be performed under an inverted microscope on day 5 and day 6. A good quality blastocyst is defined as at least Grade 2:2:2 according to Istanbul Consensus grading system. (Balaban et al., 2011).

DOCUMENTATION All patients participating in the study will be documented on a computerized CRF. This document will be related to patients' records with all relevant clinical and laboratory data from the specific IVF cycle. Through the journal system (WinIVF) used at Fertilitetscentrum, it will be possible to generate a complete list of all the variables included in the study.

Patients who have been asked to participate in the study but did not fulfill the criteria for randomization will also be registered.

STATISTICAL ANALYSIS Both an Intention-to-Treat (ITT) population and a Per Protocol (PP) population will be defined. Primary efficacy variable in this superiority study will be difference in %GQB between the two media types for each couple. Primary statistical analysis will be two-sided paired T-test regarding the mean of difference in %GQB between Standard culture media and Antioxidant media on the ITT population. A two sided 95% confidence interval for the mean difference in %GOB between the two media will be calculated. All significance tests will be two-sided and conducted at the 5% significance level.

02

Conditions studied

  • Culture Media
  • Blastocyst
  • Antioxidants
  • Embryo
  • Human
03

In context

Lead sponsor

Fertilitetscentrum AB is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 41 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Couples with female, male or unexplained infertility intending to undergo IVF
  • The couple should have received verbal and written information/consent about the study.
  • 6 or more fertilized oocytes on day 1
  • Blastocyst culture and transfer on day 5
  • Signed written consent

Exclusion criteria

Exclusion Criteria:

  • Previous participation in the study.
  • Testicular patients (TESA/TESE)
  • Fewer than 6 fertilized oocytes.
  • If split IVF is needed.
  • Total freeze on day 3
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
128 participants (actual)

Study arms

  • No intervention
    Control

    Culture media without addition of antioxidants

  • Active comparator
    Treatment

    Culture media with the addition of antioxidants

    Biological: Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of good quality blastocysts (GQB) per randomized embryo

    Time frame: 7 months

Secondary outcomes

  1. Pregnancy rate

    Time frame: 10 months

  2. Utilization rate

    Time frame: 7 months

  3. Embryo development (Kinetics) day 3,5 & 6

    Time frame: 7 months

  4. Implantation rate

    Time frame: 8 months

  5. Embryo quality dag 3,5 and 6

    Time frame: 7 months

  6. Total blastocyst rate

    Time frame: 7 months

07

Study locations

1 site
  • Fertilitetscentrum
    Gothenburg, Box 5418 40229, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Feb 2018 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 23, 2016
Start
Nov 2016
Primary completionActual
Feb 1, 2018
CompletionActual
Feb 1, 2018
Last update
Feb 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02971878
Lead sponsor
Fertilitetscentrum AB
Collaborators
Vitrolife
Responsible party
Thorir Hardarson (Laboratory Director, Fertilitetscentrum AB) — Principal investigator
First posted
Nov 23, 2016
Start date
Nov 2016
Primary completion
Feb 1, 2018
Completion
Feb 1, 2018
Last update
Feb 22, 2018

Study contacts

Thorir Hardarson, PhD
study chair · Fertilitetscentrum AB

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetylcarnitine · Acetylcysteine · Thioctic Acid

Start the discussion